Disease Driven Engineering of Multifunctional Nanoparticles and Method of Use

Description:

Mar 20/19 Copied from 2-Stroke Report:

  Chemotherapies are instrumental to cancer patient survival and management.  Despite their widespread use, chemotherapies by themselves aren’t much of a “hot topic” in cancer research because they have numerous pitfalls: they do not select cancer cells over normal healthy cells, leading to indiscriminate killing that results in toxic side effects to the patient. They also lack solubility in the blood, and are removed quickly from the blood before they can affect the tumor.

  A solution to these problems is nanomedicine. Nanoparticles encapsulating chemotherapies hold the promise of increased selectivity for tumors resulting in less off-target toxicity, improved solubility, and increased circulation times. Despite decades of excitement at these known benefits, nanoparticle therapies have not really materialized in clinical use. There are significant hurdles in technical development from the complexity of nanoparticles as multi-component, three dimensional constructs requiring careful design and engineering as well as a reproducible scale-up and manufacturing process to achieve a consistent product with the intended properties.

Dr. Bilgicer has developed a design and method to bring nanoparticle-encapsulated drugs to market.  He has created a method to create highly reproducible, targeting liposomes with fine-tuned drug ratios and drug loading. The nanoparticle production method can serve as a platform to increase the safety and efficacy of approved drugs and novel chemotherapies by providing a reliable way  to  to create cancer-targeting and less toxic drugs.

(Was already here):

Engineered nanoparticles functionalized to target malignant cells such as those comprising multiple myeloma, lymphomas, and leukemia can be used in numerous cancer therapeutics.  These nanoparticles can also be used to increase the effectiveness of current market therapeutics against cancers which exhibit drug resistance.  The nanoparticles contain a cell penetrating peptide and a target specific peptide to facilitate drug entry.  The nanoparticle target diseased cells to reduce the toxic effect of a drug on healthy organs with longer circulation time.

 

Patent Information:
For Information, Contact:
Thomas Buckley
University of Notre Dame
tbuckle2@nd.edu
Inventors:
Zihni (basar) Bilgicer
Tanyel Kiziltepe Bilgicer
Jonathan Ashley
Jared Stefanick
Keywords:
© 2019. All Rights Reserved. Powered by Inteum